|
WO2014124280A1
(en)
|
2013-02-08 |
2014-08-14 |
Institute For Myeloma & Bone Cancer Research |
Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma
|
|
GB201317928D0
(en)
*
|
2013-10-10 |
2013-11-27 |
Ucl Business Plc |
Molecule
|
|
US10174095B2
(en)
|
2014-07-21 |
2019-01-08 |
Novartis Ag |
Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor
|
|
ES2889906T3
(es)
|
2015-05-21 |
2022-01-14 |
Harpoon Therapeutics Inc |
Proteínas de unión triespecíficas y usos médicos
|
|
TWI744242B
(zh)
|
2015-07-31 |
2021-11-01 |
德商安美基研究（慕尼黑）公司 |
Egfrviii及cd3抗體構築體
|
|
TWI829617B
(zh)
|
2015-07-31 |
2024-01-21 |
德商安美基研究（慕尼黑）公司 |
Ｆｌｔ３及ｃｄ３抗體構築體
|
|
EA039859B1
(ru)
|
2015-07-31 |
2022-03-21 |
Эмджен Рисерч (Мюник) Гмбх |
Биспецифические конструкты антител, связывающие egfrviii и cd3
|
|
TWI796283B
(zh)
|
2015-07-31 |
2023-03-21 |
德商安美基研究（慕尼黑）公司 |
Ｍｓｌｎ及ｃｄ３抗體構築體
|
|
TWI811023B
(zh)
*
|
2015-08-17 |
2023-08-01 |
美商健生生物科技公司 |
抗bcma抗體，結合bcma及cd3之雙特異性抗原結合分子及其用途
|
|
JP7011600B2
(ja)
|
2016-01-12 |
2022-01-26 |
ジェイムズ リチャード ベレンソン， |
被験体の免疫状態をモニタリングするための改善された方法
|
|
TN2018000266A1
(en)
|
2016-02-03 |
2020-01-16 |
Amgen Res Munich Gmbh |
Psma and cd3 bispecific t cell engaging antibody constructs.
|
|
US20190194338A1
(en)
|
2016-02-17 |
2019-06-27 |
Seattle Genetics, Inc. |
Bcma antibodies and use of same to treat cancer and immunological disorders
|
|
JP7012665B6
(ja)
*
|
2016-05-09 |
2023-12-14 |
ブリストル－マイヤーズ スクイブ カンパニー |
Ｔｌ１ａ抗体およびその使用
|
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
|
CA3024723A1
(en)
|
2016-05-20 |
2017-11-23 |
Robert B. Dubridge |
Single domain serum albumin binding protein
|
|
US20190233533A1
(en)
|
2016-06-28 |
2019-08-01 |
Umc Utrecht Holding B.V. |
Treatment Of IgE-Mediated Diseases With Antibodies That Specifically Bind CD38
|
|
TWI781108B
(zh)
|
2016-07-20 |
2022-10-21 |
比利時商健生藥品公司 |
抗ｇｐｒｃ５ｄ抗體、結合ｇｐｒｃ５ｄ與ｃｄ３之雙特異性抗原結合分子及其用途
|
|
HRP20240767T1
(hr)
|
2016-09-14 |
2024-09-13 |
Teneoone, Inc. |
Cd3 vezujuća antitijela
|
|
BR112019012354A2
(pt)
|
2016-12-21 |
2019-11-26 |
Teneobio, Inc. |
anticorpos apenas de cadeia pesada anti-bcma
|
|
CN110121505B
(zh)
|
2016-12-28 |
2023-08-01 |
株式会社绿十字细胞治疗 |
嵌合抗原受体和表达其的自然杀伤细胞
|
|
EP3577134A1
(en)
|
2017-01-31 |
2019-12-11 |
Novartis AG |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
|
US20200179511A1
(en)
*
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
|
WO2018201056A1
(en)
|
2017-04-28 |
2018-11-01 |
Novartis Ag |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
|
BR112019023855B1
(pt)
|
2017-05-12 |
2021-11-30 |
Harpoon Therapeutics, Inc |
Proteínas de ligação à mesotelina
|
|
WO2018231944A1
(en)
|
2017-06-13 |
2018-12-20 |
Berenson James R |
Diagnostic, prognostic, and monitoring methods for solid tumor cancers
|
|
MX2019015563A
(es)
*
|
2017-06-20 |
2020-07-28 |
Teneoone Inc |
Anticuerpos anti-bcma unicamente de cadena pesada.
|
|
CN110891971B
(zh)
*
|
2017-06-20 |
2024-01-12 |
特尼奥生物股份有限公司 |
仅有重链的抗bcma抗体
|
|
WO2019000223A1
(en)
*
|
2017-06-27 |
2019-01-03 |
Nanjing Legend Biotech Co., Ltd. |
ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
|
|
JP7150820B2
(ja)
*
|
2017-08-01 |
2022-10-11 |
メディミューン，エルエルシー |
Ｂｃｍａモノクローナル抗体薬剤コンジュゲート
|
|
WO2019035938A1
(en)
|
2017-08-16 |
2019-02-21 |
Elstar Therapeutics, Inc. |
MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
|
|
CA3070468A1
(en)
|
2017-09-01 |
2019-03-07 |
Dana-Farber Cancer Institute, Inc. |
Immunogenic peptides specific to bcma and taci antigens for treatment of cancer
|
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
|
JP7084990B2
(ja)
*
|
2017-10-13 |
2022-06-15 |
ハープーン セラピューティクス，インク． |
三重特異性タンパク質と使用方法
|
|
US11999802B2
(en)
|
2017-10-18 |
2024-06-04 |
Novartis Ag |
Compositions and methods for selective protein degradation
|
|
KR20200074997A
(ko)
|
2017-11-01 |
2020-06-25 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B-세포 성숙 항원에 특이적인 항체 및 키메릭 항원 수용체
|
|
KR102845789B1
(ko)
|
2017-11-01 |
2025-08-14 |
주노 쎄러퓨티크스 인코퍼레이티드 |
B 세포 성숙 항원에 특이적인 키메라 항원 수용체 및 암호화 폴리뉴클레오타이드
|
|
US12193994B2
(en)
|
2017-11-06 |
2025-01-14 |
Juno Therapeutics, Inc. |
Combination of a cell therapy and a gamma secretase inhibitor
|
|
US11649294B2
(en)
|
2017-11-14 |
2023-05-16 |
GC Cell Corporation |
Anti-HER2 antibody or antigen-binding fragment thereof, and chimeric antigen receptor comprising same
|
|
SG11202004512XA
(en)
|
2017-11-15 |
2020-06-29 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
|
|
CA3083949A1
(en)
|
2017-11-30 |
2020-06-06 |
Novartis Ag |
Bcma-targeting chimeric antigen receptor, and uses thereof
|
|
CN112218651A
(zh)
|
2018-01-08 |
2021-01-12 |
诺华公司 |
用于与嵌合抗原受体疗法组合的免疫增强rna
|
|
US12247060B2
(en)
|
2018-01-09 |
2025-03-11 |
Marengo Therapeutics, Inc. |
Calreticulin binding constructs and engineered T cells for the treatment of diseases
|
|
US20210038659A1
(en)
|
2018-01-31 |
2021-02-11 |
Novartis Ag |
Combination therapy using a chimeric antigen receptor
|
|
EP3752203A1
(en)
|
2018-02-13 |
2020-12-23 |
Novartis AG |
Chimeric antigen receptor therapy in combination with il-15r and il15
|
|
WO2019178362A1
(en)
|
2018-03-14 |
2019-09-19 |
Elstar Therapeutics, Inc. |
Multifunctional molecules that bind to calreticulin and uses thereof
|
|
EP3774901A1
(en)
*
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
|
PE20201346A1
(es)
*
|
2018-04-13 |
2020-11-25 |
Affimed Gmbh |
Constructos de fusion de anticuerpos que se acoplan a celulas nk
|
|
WO2019222283A1
(en)
|
2018-05-14 |
2019-11-21 |
Harpoon Therapeutics, Inc. |
Binding moiety for conditional activation of immunoglobulin molecules
|
|
CA3100157A1
(en)
*
|
2018-05-16 |
2019-11-21 |
Janssen Biotech, Inc. |
Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
|
|
KR20250151605A
(ko)
*
|
2018-06-01 |
2025-10-21 |
노파르티스 아게 |
Bcma에 대한 결합 분자 및 이의 용도
|
|
JP7438988B2
(ja)
|
2018-06-13 |
2024-02-27 |
ノバルティス アーゲー |
Ｂｃｍａキメラ抗原受容体及びその使用
|
|
JP7357012B2
(ja)
*
|
2018-06-14 |
2023-10-05 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ抗体、コンジュゲート、および使用方法
|
|
WO2020004934A1
(ko)
*
|
2018-06-26 |
2020-01-02 |
에이비엘바이오 주식회사 |
항-bcma 항체 및 그 용도
|
|
CA3105448A1
(en)
|
2018-07-03 |
2020-01-09 |
Elstar Therapeutics, Inc. |
Anti-tcr antibody molecules and uses thereof
|
|
TWI838389B
(zh)
*
|
2018-07-19 |
2024-04-11 |
美商再生元醫藥公司 |
雙特異性抗-BCMAｘ抗-CD3抗體及其用途
|
|
EA202190315A1
(ru)
|
2018-07-19 |
2021-04-16 |
Ридженерон Фармасьютикалз, Инк. |
Химерные антигенные рецепторы со специфичностью к bcma и их применение
|
|
JP2021532073A
(ja)
*
|
2018-07-31 |
2021-11-25 |
アムジェン リサーチ （ミュニック） ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Ｂｃｍａ−ｃｄ３二重特異性抗体のための投与レジメン
|
|
EA202190468A1
(ru)
|
2018-08-08 |
2021-07-06 |
Драгонфлай Терапьютикс, Инк. |
Мультиспецифические связывающие белки, которые связывают bcma, nkg2d и cd16, и способы их применения
|
|
EP3844267B1
(en)
|
2018-08-31 |
2025-06-25 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
|
US12195544B2
(en)
|
2018-09-21 |
2025-01-14 |
Harpoon Therapeutics, Inc. |
EGFR binding proteins and methods of use
|
|
CN113286817B
(zh)
|
2018-09-25 |
2025-01-28 |
哈普恩治疗公司 |
Dll3结合蛋白及使用方法
|
|
US12116415B2
(en)
|
2018-10-09 |
2024-10-15 |
Single Cell Technology, Inc. |
Anti-BCMA antibodies
|
|
MX2021005024A
(es)
|
2018-11-01 |
2021-07-21 |
Juno Therapeutics Inc |
Metodos de tratamiento que utilizan receptores de antigenos quimericos especificos para antigeno de maduracion de celulas b.
|
|
BR112021008486A2
(pt)
*
|
2018-11-01 |
2021-10-26 |
Shandong New Time Pharmaceutical Co., Ltd |
Anticorpo biespecífico e seu uso
|
|
US20200199232A1
(en)
*
|
2018-12-19 |
2020-06-25 |
City Of Hope |
Baff-r bispecific t-cell engager antibody
|
|
WO2020160375A1
(en)
*
|
2019-02-01 |
2020-08-06 |
Glaxosmithkline Intellectual Property Development Limited |
Combination treatments for cancer comprising belantamab mafodotin and an anti ox40 antibody and uses and methods thereof
|
|
GB2597851B
(en)
|
2019-02-21 |
2024-05-29 |
Marengo Therapeutics Inc |
Antibody molecules that bind to NKP30 and uses thereof
|
|
EP3927744A1
(en)
|
2019-02-21 |
2021-12-29 |
Marengo Therapeutics, Inc. |
Multifunctional molecules that bind to t cell related cancer cells and uses thereof
|
|
EP3930763A1
(en)
|
2019-02-25 |
2022-01-05 |
Novartis AG |
Mesoporous silica particles compositions for viral delivery
|
|
KR20210133261A
(ko)
*
|
2019-02-26 |
2021-11-05 |
소렌토 쎄라퓨틱스, 인코포레이티드 |
Bcma에 결합하는 항원 결합 단백질
|
|
US12448429B2
(en)
|
2019-03-06 |
2025-10-21 |
Dana-Farber Cancer Institute, Inc. |
T cell receptors specific to b-cell maturation antigen for treatment of cancer
|
|
US20230074800A1
(en)
|
2019-03-21 |
2023-03-09 |
Novartis Ag |
Car-t cell therapies with enhanced efficacy
|
|
MA55372A
(fr)
|
2019-03-21 |
2022-01-26 |
Regeneron Pharma |
Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie
|
|
AU2020252556B2
(en)
|
2019-04-05 |
2026-02-05 |
Teneobio, Inc. |
Heavy chain antibodies binding to PSMA
|
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
|
EP3733707A1
(en)
*
|
2019-04-30 |
2020-11-04 |
Celyad S.A. |
Car t-cells targeting bcma and uses thereof
|
|
CA3134918A1
(en)
*
|
2019-05-03 |
2020-11-12 |
John Lee |
Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
|
|
US12516128B2
(en)
|
2019-05-14 |
2026-01-06 |
Harpoon Therapeutics, Inc. |
EpCAM binding proteins and methods of use
|
|
TWI905099B
(zh)
|
2019-05-21 |
2025-11-21 |
瑞士商諾華公司 |
Cd19 結合分子及其用途
|
|
CR20210622A
(es)
|
2019-06-14 |
2022-06-27 |
Teneobio Inc |
Anticuerpos multiespecíficos de cadena pesada que se unen a cd22 y cd3
|
|
CN111269315B
(zh)
*
|
2019-06-19 |
2022-04-08 |
北京智仁美博生物科技有限公司 |
针对bcma的单克隆抗体
|
|
US12540190B2
(en)
|
2019-07-30 |
2026-02-03 |
Shanghai Hansoh Biomedical Co., Ltd. |
Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof
|
|
WO2021092060A1
(en)
*
|
2019-11-05 |
2021-05-14 |
Engmab Sarl |
Methods of treatment
|
|
DK3819007T3
(da)
|
2019-11-11 |
2024-09-30 |
Amgen Res Munich Gmbh |
Doseringsplan for anti-bcma-midler
|
|
CN114761037A
(zh)
|
2019-11-26 |
2022-07-15 |
诺华股份有限公司 |
结合bcma和cd19的嵌合抗原受体及其用途
|
|
MX2022006714A
(es)
*
|
2019-12-06 |
2022-08-08 |
Regeneron Pharma |
Métodos de tratamiento del mieloma múltiple con anticuerpos anti-bcma x anti-cd3 bisespecíficos.
|
|
CA3160765A1
(en)
|
2019-12-10 |
2021-06-17 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
WO2021132746A1
(en)
*
|
2019-12-24 |
2021-07-01 |
Abl Bio, Inc. |
Anti-bcma/anti-4-1bb bispecific antibodies and uses thereof
|
|
JP7743406B2
(ja)
|
2019-12-16 |
2025-09-24 |
２セブンティ バイオ インコーポレイテッド |
抗ｂｃｍａ ｃａｒ抗体、コンジュゲートおよび使用方法
|
|
CN114981309B
(zh)
*
|
2020-01-03 |
2023-08-25 |
博奥信生物技术（南京）有限公司 |
结合bcma的抗体及其用途
|
|
EP4084823A4
(en)
|
2020-01-03 |
2024-05-15 |
Marengo Therapeutics, Inc. |
ANTI-TCR ANTIBODY MOLECULES AND THEIR USES
|
|
KR20220146530A
(ko)
|
2020-02-27 |
2022-11-01 |
노파르티스 아게 |
키메라 항원 수용체-발현 세포의 제조 방법
|
|
BR112022016633A2
(pt)
|
2020-02-27 |
2022-12-13 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
|
CN115605512A
(zh)
*
|
2020-03-13 |
2023-01-13 |
詹森生物科技公司（Us） |
用于调节δ链介导的免疫的材料和方法
|
|
TW202144425A
(zh)
*
|
2020-04-17 |
2021-12-01 |
大陸商上海翰森生物醫藥科技有限公司 |
特異性抗原結合分子，其製備方法及醫藥用途
|
|
UY40898A
(es)
*
|
2020-04-29 |
2024-10-15 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecíficos con regiones constantes de cadena pesada modificadas
|
|
MX2022013453A
(es)
|
2020-04-29 |
2022-11-16 |
Teneobio Inc |
Anticuerpos de cadena pesada multiespecificos con regiones constantes de cadena pesada modificadas.
|
|
CA3182697A1
(en)
*
|
2020-05-11 |
2021-11-18 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
CN113637073B
(zh)
*
|
2020-05-11 |
2024-04-12 |
上海赛比曼生物科技有限公司 |
Bcma抗体及其制备和应用
|
|
US20210363252A1
(en)
|
2020-05-19 |
2021-11-25 |
Janssen Biotech, Inc. |
Compositions comprising a t cell redirection therapeutic and a vla-4 adhesion pathway inhibitor
|
|
KR20230024967A
(ko)
|
2020-06-11 |
2023-02-21 |
노파르티스 아게 |
Zbtb32 억제제 및 이의 용도
|
|
EP4545569A3
(en)
*
|
2020-06-30 |
2025-10-08 |
Harbour Biomed (Shanghai) Co., Ltd |
Binding protein having h2l2 and hcab structures
|
|
IL299027A
(en)
|
2020-06-30 |
2023-02-01 |
Teneobio Inc |
Multispecific antibodies that bind BCMA
|
|
CN114075287B
(zh)
|
2020-08-18 |
2023-07-21 |
湖南远泰生物技术有限公司 |
人源化bcma抗体和bcma-car-t细胞
|
|
WO2022040586A2
(en)
|
2020-08-21 |
2022-02-24 |
Novartis Ag |
Compositions and methods for in vivo generation of car expressing cells
|
|
IL300884A
(en)
*
|
2020-09-14 |
2023-04-01 |
Pfizer |
Treatment methods and uses for cancer treatment
|
|
EP4214233A1
(en)
|
2020-09-16 |
2023-07-26 |
Amgen Inc. |
Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
|
|
US20240002539A1
(en)
*
|
2020-11-03 |
2024-01-04 |
Ab Studio Inc. |
Multispecific antibodies and uses thereof
|
|
JP2023549780A
(ja)
|
2020-11-04 |
2023-11-29 |
ジュノー セラピューティクス インコーポレイテッド |
改変されたインバリアントｃｄ３免疫グロブリンスーパーファミリー鎖遺伝子座からキメラ受容体を発現する細胞ならびに関連するポリヌクレオチドおよび方法
|
|
CN114524878B
(zh)
*
|
2020-11-23 |
2024-08-02 |
康诺亚生物医药科技（成都）有限公司 |
一种双特异性抗体及其用途
|
|
CN114573703A
(zh)
*
|
2020-12-02 |
2022-06-03 |
康诺亚生物医药科技（成都）有限公司 |
一种t细胞衔接器治疗剂的开发和应用
|
|
WO2022135468A1
(zh)
*
|
2020-12-23 |
2022-06-30 |
信达生物制药(苏州)有限公司 |
抗bcma×cd3双特异性抗体及其用途
|
|
SI4284512T1
(sl)
|
2021-01-28 |
2025-06-30 |
Regeneron Pharmaceuticals, Inc. |
Sestavki in postopki za zdravljenje sindroma sproščanja citokinov
|
|
PE20241170A1
(es)
|
2021-02-16 |
2024-05-28 |
Janssen Pharmaceutica Nv |
Anticuerpo triespecifico dirigido a bcma, gprc5d, y cd3
|
|
US12162945B2
(en)
|
2021-03-05 |
2024-12-10 |
Immunome, Inc. |
EPHA2 antibodies
|
|
BR112023019484A2
(pt)
|
2021-03-24 |
2023-12-05 |
Janssen Biotech Inc |
Anticorpo triespecífico que tem como alvo cd79b, cd20 e cd3
|
|
KR20240004462A
(ko)
|
2021-04-08 |
2024-01-11 |
마렝고 테라퓨틱스, 인크. |
Tcr에 결합하는 다기능성 분자 및 이의 용도
|
|
AU2022267891A1
(en)
|
2021-04-27 |
2023-11-09 |
Novartis Ag |
Viral vector production system
|
|
CN117396231A
(zh)
|
2021-04-30 |
2024-01-12 |
新基公司 |
使用抗BCMA抗体药物缀合物（ADC）与γ分泌酶抑制剂（GSI）的组合的组合疗法
|
|
TW202309522A
(zh)
|
2021-05-11 |
2023-03-01 |
美商健生生物科技公司 |
用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
|
|
MX2023014139A
(es)
|
2021-05-28 |
2023-12-13 |
Janssen Biotech Inc |
Bcma como un objetivo para anticuerpos de redireccionamiento de celulas t en linfomas de celulas b.
|
|
CN119569887A
(zh)
*
|
2021-06-24 |
2025-03-07 |
益科思特(北京)医药科技发展有限公司 |
结合bcma和cd3的双特异性抗体及其制备方法与应用
|
|
CN115569191A
(zh)
*
|
2021-07-05 |
2023-01-06 |
山东新时代药业有限公司 |
一种重组人源化抗bcma/cd3双特异性抗体冻干制剂
|
|
WO2023020474A1
(en)
*
|
2021-08-16 |
2023-02-23 |
Utc Therapeutics (Shanghai) Co., Ltd. |
Bcma targetting antibodies and uses thereof in cancer therapies
|
|
WO2023021477A1
(en)
|
2021-08-20 |
2023-02-23 |
Novartis Ag |
Methods of making chimeric antigen receptor–expressing cells
|
|
KR20240099259A
(ko)
|
2021-10-14 |
2024-06-28 |
아스널 바이오사이언시스, 인크. |
공동 발현된 shrna 및 논리 게이트 시스템을 갖는 면역 세포
|
|
IL312365A
(en)
*
|
2021-10-27 |
2024-06-01 |
Janssen Biotech Inc |
Methods for enhanced bcma immunohistochemistry detection in human and monkey tissue
|
|
KR20240099376A
(ko)
|
2021-11-03 |
2024-06-28 |
얀센 바이오테크 인코포레이티드 |
암 치료 및 bcmaxcd3 이중특이성 항체의 효능을 향상시키는 방법
|
|
JP2024540304A
(ja)
|
2021-11-03 |
2024-10-31 |
ヤンセン バイオテツク，インコーポレーテツド |
抗ｃｄ３８抗体による治療におけるコルチコステロイドの減少
|
|
JP2024544523A
(ja)
*
|
2021-11-10 |
2024-12-03 |
ヤンセン バイオテツク，インコーポレーテツド |
二重特異性ｂｃｍａ／ｃｄ３抗体を含む安定な製剤
|
|
EP4428156A4
(en)
*
|
2021-12-03 |
2026-03-04 |
Shandong Simcere Biopharmaceutical Co., Ltd. |
ANTI-BCMA NANOBODY AND USE THEREOF
|
|
US20230357446A1
(en)
|
2022-04-11 |
2023-11-09 |
Regeneron Pharmaceuticals, Inc. |
Compositions and methods for universal tumor cell killing
|
|
CN117003871A
(zh)
*
|
2022-04-28 |
2023-11-07 |
北京天广实生物技术股份有限公司 |
结合bcma和cd3的抗体及其用途
|
|
CN116023504B
(zh)
*
|
2022-06-07 |
2025-09-30 |
江苏蒙彼利生物科技有限公司 |
双特异性嵌合抗原受体（car）及其制备方法
|
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
|
KR20250097946A
(ko)
|
2022-11-02 |
2025-06-30 |
얀센 바이오테크 인코포레이티드 |
암을 치료하는 방법
|
|
WO2024102954A1
(en)
|
2022-11-10 |
2024-05-16 |
Massachusetts Institute Of Technology |
Activation induced clipping system (aics)
|
|
KR20250143880A
(ko)
*
|
2022-12-02 |
2025-10-02 |
아티바 바이오테라퓨틱스, 인크. |
항-bcma 항체 또는 그의 항원-결합 단편, 및 그를 포함하는 키메라 항원 수용체
|
|
CN117186228B
(zh)
*
|
2022-12-06 |
2024-03-22 |
成都赛恩吉诺生物科技有限公司 |
包含长cdr3序列的抗人bcma纳米抗体的双特异性抗体及应用
|
|
WO2024124088A1
(en)
*
|
2022-12-09 |
2024-06-13 |
Sana Biotechnology, Inc. |
Bcma-specific antibody constructs and compositions thereof
|
|
IL322545A
(en)
|
2023-02-17 |
2025-10-01 |
Regeneron Pharma |
Induced NK cells responding to bispecific CD3/TAA antibodies
|
|
TW202440636A
(zh)
|
2023-03-21 |
2024-10-16 |
美商傳記５５有限公司 |
Ｃｄ１９／ｃｄ３８多特異性抗體
|
|
US20250242019A2
(en)
*
|
2023-04-19 |
2025-07-31 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
EP4709755A1
(en)
|
2023-05-09 |
2026-03-18 |
Janssen Biotech, Inc. |
Pharmaceutical compositions comprising a bispecific bcma/cd3 antibody at high concentration
|
|
CN121666232A
(zh)
|
2023-05-31 |
2026-03-13 |
开普斯坦治疗公司 |
脂质纳米颗粒制剂和组合物
|
|
WO2024251154A1
(zh)
|
2023-06-06 |
2024-12-12 |
信达生物制药(苏州)有限公司 |
抗gprc5d/bcma/cd3三特异性抗体的制备及其用途
|
|
WO2025059162A1
(en)
|
2023-09-11 |
2025-03-20 |
Dana-Farber Cancer Institute, Inc. |
Car-engager containing il-2 variants to enhance the functionality of car t cells
|
|
WO2025076127A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025076113A1
(en)
|
2023-10-05 |
2025-04-10 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids with conserved spacing and lipid nanoparticles
|
|
WO2025096717A1
(en)
*
|
2023-11-01 |
2025-05-08 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
WO2025094107A1
(en)
|
2023-11-01 |
2025-05-08 |
Janssen Biotech, Inc. |
Methods for treating high-risk smoldering multiple myeloma
|
|
WO2025131075A1
(zh)
*
|
2023-12-21 |
2025-06-26 |
上海君实生物医药科技股份有限公司 |
抗cd3和抗cd3多特异性抗体及用途
|
|
US20250242018A1
(en)
|
2024-01-26 |
2025-07-31 |
Regeneron Pharmaceuticals, Inc. |
Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
|
|
TW202540428A
(zh)
|
2024-01-26 |
2025-10-16 |
美商雷傑納榮製藥公司 |
使用漿細胞耗乏劑及／或ｂ細胞耗乏劑遏制宿主抗ａａｖ抗體反應且實現ａａｖ轉導及重複給藥的方法及組成物
|
|
US20250276092A1
(en)
|
2024-03-01 |
2025-09-04 |
Regeneron Pharmaceuticals, Inc. |
Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
|
|
WO2025217454A2
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Ionizable cationic lipids and lipid nanoparticles
|
|
WO2025217452A1
(en)
|
2024-04-11 |
2025-10-16 |
Capstan Therapeutics, Inc. |
Constrained ionizable cationic lipids and lipid nanoparticles
|
|
WO2025231372A2
(en)
|
2024-05-03 |
2025-11-06 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma with car-t cells and bispecific antibodies
|
|
WO2025243241A1
(en)
|
2024-05-23 |
2025-11-27 |
Janssen Biotech, Inc. |
Methods for treating multiple myeloma
|
|
WO2026033437A1
(en)
|
2024-08-07 |
2026-02-12 |
Janssen Biotech, Inc. |
Methods of treating autoimmune diseases comprising the administration of anti-bcma therapeutics
|
|
WO2026050572A2
(en)
|
2024-08-29 |
2026-03-05 |
Marengo Therapeutics, Inc. |
Multifunctional molecules binding to tcr and uses thereof
|